key: cord-0796228-e95rmwuh
authors: Qiang, Min; Ma, Peixiang; Li, Yu; Liu, Hejun; Harding, Adam; Min, Chenyu; Liu, Lili; Yuan, Meng; Ji, Qun; Tao, Pingdong; Shi, Xiaojie; Li, Zhean; Wang, Fulian; Zhang, Yu; Wu, Nicholas C.; Lee, Chang-Chun D.; Zhu, Xueyong; Gilbert-Jaramillo, Javier; Saxena, Abhishek; Huang, Xingxu; Wang, Hou; James, William; Dwek, Raymond A.; Wilson, Ian A.; Yang, Guang; Lerner, Richard A.
title: Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago
date: 2020-11-06
journal: bioRxiv
DOI: 10.1101/2020.11.06.370676
sha: 255755acf9e9320fc2da2699dca1924758ddd1cf
doc_id: 796228
cord_uid: e95rmwuh

Combinatorial antibody libraries not only effectively reduce antibody discovery to a numbers game, but enable documentation of the history of antibody responses in an individual. The SARS-CoV-2 pandemic has prompted a wider application of this technology to meet the public health challenge of pandemic threats in the modern era. Herein, we used a combinatorial human antibody library constructed 20 years before the COVID-19 pandemic to discover three highly potent antibodies that selectively bind SARS-CoV-2 spike protein and neutralize authentic SARS-CoV-2 virus. Compared to neutralizing antibodies from COVID-19 patients with generally low somatic hypermutation (SHM), these antibodies contain over 13-22 SHMs, many of which are involved in specific interactions in crystal structures with SARS-CoV-2 spike RBD. The identification of these somatically mutated antibodies in a pre-pandemic library raises intriguing questions about the origin and evolution of human immune responses to SARS-CoV-2.

determined by biolayer interferometry (Figure 3B -3E). S-B8, S-D4, and S-E6 showed 109 KD values of 170 pM, 10 pM and 110 pM, respectively, with S-D4 displaying the highest 110 affinity due to its greatly reduced off-rate ( Figure 3C ). 111 We also tested with natural mutants of SARS-CoV-2 spike proteins that have been 112 clinically associated with more severe illness and longer hospital stays. Three mutants, 113 i.e. D215H (mut 1), S247R (mut 2) and D614G (mut 3), isolated from patients requiring Table 1 ). Fab S-B8 and S-E6 bind the receptor binding site (RBS) with different approach angles ( Figure 6A ) and sterically compete with ACE2 for RBD binding, 153 consistent with the competition assay ( Figure 3A ). S-B8 interacts mainly using its heavy 154 chain, which contributes 73% of the buried surface area (BSA, 737 of 1010 Å 2 ) ( Figure   155 6B) and 12 of 16 polar contacts (Supplementary Table 2 ). S-E6 predominately uses its 156 light chain, which contributes 63% of the BSA (530 of 847 Å 2 ) and 16 of 19 polar contacts 157 (Supplementary Table 2 ). Light chain dominant interactions are less common in 158 antibodies (28, 29) . 159 IgBLAST analysis (30) suggests S-B8 is derived from IGHV3-66, a germline that is 160 highly similar to IGHV3-53 (Supplementary Figure 5) . We previously reported that 161 IGHV3-53 antibodies from convalescent patients, with minimal SHM and high potency, 162 have two key germline motifs in CDRH1 and CDRH2 that are primarily used for 163 recognition of SARS-CoV-2 S-RBD, namely 32NY33 and 53SGGS56 (31, 32 the RBD ridge interact with VH Y52 and VL Y27d via π-π interactions ( Figure 6D ). Of note,

F486 is also buried in a pocket at the heavy-light chain interface in COVA2-39, which is 178 an IGHV3-53 antibody, as well as other antibodies that bind in RBS-B mode (34).

Altogether, 19 of 29 S-B8 epitope residues are shared with 19 of 21 COVA2-39 epitope 180 residues, with16 corresponding to ACE2 binding residues (Supplementary Figure 8) .

S-E6 is an IGHV4-31 antibody. Interestingly, SHM introduces a 33NY34 sequence in a in binding mode A ( Figure 6F ). VH Y34 and VH A97 form two hydrogen bonds with N487 188 of the S-RBD ( Figure 6E ), which differ from Y33 in IGHV3-53 antibodies ( Figure 6F ). F486, 189 along with N487, interact with a hydrophobic pocket formed by VH Y34, A97, H101 and 190 I102 of S-E6 and also make π-π and cation-π interactions ( Figure 6E ). However, the S-E6 

For over a century, serology has been used to document the origin and presence of 220 infectious agents in patients. Classically, serology depends on the actual presence of 221 specific antibody proteins in the blood. Their target is thought to be the infectious agent, 222 and their presence indicates a relatively recent exposure. By contrast, antibody libraries 223 are nucleic acid based, and include genetic material from memory cells. As such, they 224 provide a record of all of the antibodies that an individual has made, irrespective of 225 whether they are currently being produced. This "fossil record" enabled us to discover was generated could have been exposed to SARS-CoV-2 or a similar virus.

Although the antibody library used here was established in 1999 before the SARS and CoV-2 convalescent patients contain only a few amino-acid mutations (3, 8, 9, 36, 37) . has direct relevance in the clinical setting, where a major concern in antibody therapy is 282 the high mutation rate of viral spike proteins, which can render prior highly specific compositions.

The cell-cell fusion assay was established according to a previous report (40) 

667 668

Round 1-pH 2.2 Elution 1×10 13 2×10 6

Round 2-pH 2.2 Elution 1×10 13 2×10 7

Round 3-hACE2-ECD Elution 3×10 13 4×10 9 * Output vs. panning round with antigen S-RBD-hFc and negative control hFc.

A. D. E.

10 nM 72% 75% 85% 87%

1 nM 50% 17% 49% 33%

F. 

S-E6 Fab 

Supplementary Figure 6. Germline sequences and somatic hypermutation (SHM)

Germline sequences are aligned to heavy and light chain sequences 755 for each antibody

Autoreactivity detection of selected antibodies

(D) were tested by using a HEp-2 cell based antinuclear-antibody kit. The S-B8 putative 772 germline antibody was generated by mutating the SHMs of S-B8 back to the germline 773 sequence of IGHV3-66 as shown in Supplementary Figure 6. Positive control (PC) (E) and negative control (NC) (F) are from serum of patients with or without autoimmune 775 disease